Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003:1:e009.
doi: 10.1621/nrs.01009. Epub 2003 Sep 27.

Therapeutic androgen receptor ligands

George F Allan  1 , Zhihua Sui
Affiliations

Therapeutic androgen receptor ligands

George F Allan et al. Nucl Recept Signal. 2003.

Abstract

In the past several years, the concept of tissue-selective nuclear receptor ligands has emerged. This concept has come to fruition with estrogens, with the successful marketing of drugs such as raloxifene. The discovery of raloxifene and other selective estrogen receptor modulators (SERMs) has raised the possibility of generating selective compounds for other pathways, including androgens (that is, selective androgen receptor modulators, or SARMs).

PubMed Disclaimer

Figures

Figure 1
Figure 1. : Non steroidal SARMs
1, Flutamide; 2, Nilutamide; 3, Bicalutamide
Figure 2
Figure 2. : 2 quinolone and coumarins
See text for more details.
Figure 3
Figure 3. : Phthalimide analogs
See text for more details
Figure 4
Figure 4. : Bicalutamide derivatives
See text for more details
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Carmina E., Lobo R. A. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf) 2002;57:231–4. - PubMed
    1. Dalton J.T., Miller D.D., Yin D., He Y., inventors. Preparation of 3-phenoxypropionic acid 4-nitro-3-trifluoromethylbenzamides as selective androgen receptor modulators. 2002.
    1. Diamanti-Kandarakis E. Current aspects of antiandrogen therapy in women. Curr Pharm Des. 1999;5:707–23. - PubMed
    1. Flynn V., Hellstrom W. J. Androgen deficiency in the aging male: pathophysiology, diagnosis, and treatment alternatives. Curr Urol Rep. 2001;2:473–9. - PubMed
    1. Hamann L. G., Mani N. S., Davis R. L., Wang X. N., Marschke K. B., Jones T. K. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071) J Med Chem. 1999;42:210–2. - PubMed

LinkOut - more resources